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Abstract
Background: Several different microarray platforms area v a i l a b l ef o rm e a s u r i n gg e n ee x p r e s s i o n .
There are disagreements within the microarray scientific community for intra- and inter-platform
consistency of these platforms. Both high and low consistencies were demonstrated across
different platforms in terms of genes with significantly differential expression. Array studies for
gene expression are used to explore biological causes and effects. Therefore, consistency should
eventually be evaluated in a biological setting to reveal the functional differences between the
examined samples, not just a list of differentially expressed genes (DEG). In this study, we
investigated whether different platforms had a high consistency from the biologically functional
perspective.
Results: DEG data without filtering the different probes in microarrays from different platforms
generated from kidney samples of rats treated with the kidney carcinogen, aristolochic acid, in five
test sites using microarrays from Affymetrix, Applied Biosystems, Agilent, and GE health platforms
(two sites using Affymetrix for intra-platform comparison) were input into the Ingenuity Pathway
Analysis (IPA) system for functional analysis. The functions of the DEG lists determined by IPA
were compared across the four different platforms and two test sites for Affymetrix platform.
Analysis results showed that there is a very high level of consistency between the two test sites
using the same platform or among different platforms. The top functions determined by the
different platforms were very similar and reflected carcinogenicity and toxicity of aristolochic acid
in the rat kidney.
Conclusion: Our results demonstrate that highly consistent biological information can be
generated from different microarray platforms.
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Microarray technology has become one of the most
important approaches to globally reveal gene expression
changes to identify genes associated with biological
processes of interests. At present, several different
microarray platforms are commercially available. The
different platforms often have diverse types and various
numbers of gene probes. Even for the probes corre-
sponding to the same genes, there are usually various
levels of binding affinity and specificity in different
platforms. Therefore, questions are raised on whether the
different microarray platforms can generate similar gene
expression results [1-4]. To answer the questions, the
MicroArray Quality Control (MAQC) project compared
gene expression data generated from different microarray
platforms for a set of common samples and found
certain consistencies among the different platforms for
the differentially expressed genes (DEG) [5,6].
Microarray methods are commonly used for examining
thousands of genes simultaneously to reveal biological
functional differences between examined samples.
Therefore, biological functions should be considered as
the ultimate endpoints for comparison of consistency
across different microarray platforms. If different micro-
array platforms result in different DEGs but the same
biological functions, we should acknowledge that these
platforms are indeed comparable and reproducible
because they tell us the same results. Although DEGs
can be diverse when the experiments are performed at
various times, in different laboratories or using dissim-
ilar platforms, if most of the DEGs are true discoveries
and enough of them are filled into distinct biological
functional pathways, the altered biological functions can
be identified. Therefore, it is logically hypothesized that
high cross-platform concordance can be reached at
biological function level.
In this study, we used the MAQC project data generated
from kidney samples of rats treated with aristolochic acid
(AA) [5]. AA is an active component of herbal drugs, but
it is a nephrotoxin and carcinogen. A high prevalence of
urothelial carcinoma was found in patients that devel-
oped nephropathy due to AA exposure [7-9]. Animal
models also demonstrated that AA treatment resulted in
renal failure in rodents [10], and tumors in the kidney,
forestomach, and other tissues of rats and mice [11-13].
AA was identified among the most potent 2% of the
carcinogens [14]. The International Agency for Research
on Cancer (IARC) has classified products containing AA
as human carcinogens [15]. Our previous studies have
demonstrated that AA exposure produced DNA adducts
and mutations in rat kidney [16,17] and induced
carcinogenesis revealed by gene expression analysis of
t h es a m ek i d n e ys a m p l e s[ 1 8 ] .I fd i f f e r e n tm i c r o a r r a y
platforms are comparable for biologically functional
analysis, we would expect these toxicological processes
or functions to appear on the top functions altered in the
AA treatment in each testing platform.
Results
Significant gene lists and common DEGs in
different platforms
Unlike the MAQC study [5] in which the common genes
across all platforms were used as a starting point for
platform comparison, we used all genes in each platform
microarray to independently select DEGs. Genes with
q < 0.01 were considered as significantly changed. AA
treatment of rats resulted in a number of DEGs in rat
kidney, a carcinogenic target tissue of the carcinogen. The
1303 DEGs from Affymetrix test site 1 (AFX_1), 928 in
Affymetrix test site 2 (AFX_2), 559 in Applied Biosystems
site (ABI), 611 in Agilent (AG1), and 2346 in GE Health
(GEH) were selected from 13713, 13713, 16280, 16135
and 12576 unique genes in each platform, respectively
(See additional file 1: DEGs). Figure 1 is a heat map to
compare the common DEGs from the different test sites.
There are 130 DEGs common to all the five test sites, 252
DEGs common to four sites, 343 DEGs common to three
sites, 545 DEGs common to two sites and 1970 present
Figure 1
Heat map of differentially expressed genes from 5
platforms/sites. The green color indicates genes that are
down-regulated; red color represents up-regulated genes;
and black color means missing values. The platform number
indicates in how many platforms a gene appears.
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two platforms is shown in Table 1. The percentages of
common DEGs are low, ranging from 9% to 34%, except
for the percentage between AFX_1 and AFX_2. The low
percentages of common DEGs among the different
platforms mainly resulted from the different gene probes
in different platforms. There are only 5824 genes
common to all the 4 platforms.
Intra-platform comparison of biological processes
To compare the consistency of intra-platform microarray
studies, two sets of data generated from two test sites for
Affymetrix (AFX_1 and AFX_2) were used. The two DEG
lists were imported to Ingenuity Pathway Analysis
system (IPA) to identify the functions that were altered
by AA treatment. The altered function processes are listed
in Additional file 2. The two sets of function processes
corresponding to the two DEG lists were compared and
the percentages of common functions at a given number
of functions are displayed in Figure 2. These two
function lists exhibit high levels of overlap, whereas
the control function lists from randomly chosen genes
show much lower percentages of overlapping functions.
The percentage of overlapping functions for the first 5
ranks are over 80%, and remains stable at about 70%.
The control function lists, however, show very low
concordance. There are no common functions between
the control function lists for the top 10 functions, and
t h ep e r c e n t a g eo fo v e r l a p p i n gfunctions increases slightly
when more functions are considered. Table 2 is a
snapshot of the overlapping at the top 30 functions
from Figures 2 and 3. The percentage of common
functions between AFX_1 and AFX_2 is the highest
(77%) among the comparisons, indicating that the intra-
platform reproducibility for gene expression is better
than inter-platform reproducibility in terms of biological
functions.
Inter-platform comparison of biological processes
Functional processes from the four platforms, ABI, AG1,
GEH and AFX (AFX_1 was used for inter-platform
comparison) were analyzed and compared. The percen-
tages of overlapping AA-altered functions between any
pair of two platforms vs. certain number of top functions
are graphed and displayed in Figure 3. The patterns for
the changes of common function ratio with number of
top function are very similar in the six comparisons
between the different platform microarrays. The highest
concordance between platforms appear around top 10
functions, indicating that the major functional changes
induced by AA treatment in rat kidney were commonly
discovered by microarray analysis of gene expression
from different platforms. The percentages of common
functions at around top 50 of functions reach to the
lowest and then slowly increase with function numbers
in all of the comparisons. The percentages of common
functions between the different platforms are from 47 to
70% while those between the control function lists are
very low, from 0 to 10% (Table 2).
A comparison across all of the 4 platforms also shows
high concordance for the top 20 functions (45%,
Figure 4), considering that only 4% DEGs (130 DGEs
common to all four sites/3240 total DGEs that were used
for the analysis) are common in the gene lists from the
different platforms (Figure 1). In contrast, the percentage
of common functions among the 4 platforms in the
Table 1: Percentage of common differentially expressed genes
between any two platforms/sites
AFX_1 AFX_2 ABI AG1 GEH
AFX_1 100
AFX_2 52 100
ABI 13 14 100
AG1 29 34 16 100
GEH 31 25 9 18 100
Figure 2
Intra-platform overlaps of AA-altered biological
functions. Common AA-altered functions between the two
function lists from AFX_1 and AFX_2 for a given number of
functions are shown as blue color. The common functions
between the control function lists generated from randomly
selected genes for each of the test sites are displayed as red.
Table 2: Percentage of common functions in the top 30 functions
between any two platforms/sites
AFX_1 AFX_2 ABI AG1 GEH
AFX_1 100
AFX_2 77 (3) 100
ABI 57 (3) 53 (0) 100
AG1 63 (0) 67 (3) 57 (10) 100
GEH 70 (7) 63 (3) 47 (7) 63 (7) 100
Note: The numbers inside brackets represent the overlapping
percentages of the top 30 functions from the control function lists.
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top functions are selected (Figure 4).
Major biological processes changed by AA exposure
in rat kidney
To examine whether each platform/site could reveal
similar ongoing biological processes in rat kidneys
exposed to AA, we compared the top 10 functions
identified by IPA from the different platforms (Table 3).
Since the major functions changed by a treatment
normally appear to be the most significant, the top
functions should reflect AA’s carcinogenic characters in
rat kidney. As expected, the major functions from all 5
platform/sites were carcinogenesis-related, such as can-
cer, tumor, neoplasm and tumorigenesis. Other func-
tions like inflammatory disorder might reveal other
toxicities of AA in rat kidney. When the top 20 functions
Figure 3
Inter-platform overlap between any two platforms in terms of AA-altered biological functions. The percentage of
common functions is displayed against a given number of functions. The treatment is shown in blue and the randomly selected
control is displayed in red. AFX, ABI, AG1 and GEH represent Affymetrix, Applied Biosystems, Agilent and GE Healthcare
microarrays, respectively.
Figure 4
Inter-platform overlap among all of the four
platforms in terms of AA-altered biological functions.
The percentages of common functions are displayed against a
given number of functions. The treatment is shown in blue
a n dt h er a n d o m l ys e l e c t e dc o n t r o li sd i s p l a y e di nr e d .
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remained as the main subject across all of the platforms
(data not shown). In contrast, the top 10 functions
derived from the control gene lists were diverse and
inconsistent across the platforms/sites, and primarily
were not cancer-related (Table 4).
Discussion
The main purpose of gene expression studies using
microarrays is to reveal the underlying biological
differences between the two groups of samples. For
example, examination of the lists of DEGs between
controls and chemical-treated samples could reveal
whether the chemical is toxic or not. DEG lists may
change depending on the experiment, laboratory and
platforms due to experimental variability, sample size,
dissimilar probes in microarrays, different binding sites
of probes for genes, and diverse methods for data
normalization and selection. Therefore, DEG lists gener-
ated from identical RNA preparations could be consider-
ably divergent if the microarray experiments are
performed in different sites or with dissimilar microarray
platforms [1,3]. The different DEG lists from various
sites/platforms, however, still can be considered compar-
able if they reveal the same biological truth between the
two groups of samples. It should also be pointed out that
the higher percentage of overlapping functions compared
to overlapping genes may be attributed to the fact that
each function contains many genes.
In our analysis, the DEG lists identified from the
platforms are very different because we did not use the
common set of genes in the platforms for their selection.
Only about 4% DEGs are common in all of the lists
(Figure 1) and 9–34% DEGs are common between any
two of the platforms (Table 1). In contrast, IPA analysis
of these different lists resulted in high concordances of
biological functions within one platform, between any
two platforms and among all the platforms, especially
for the top functions. The reproducibility of AA-altered
functions for intra-platform is very high. This result is
not unexpected because the microarrays tested in the
different sites have the same gene probes and chemistries
and the DEG lists from the two test sites are also similar.
Although the percentages of common functions among
the different platforms are a little bit lower than that for
intra-platform, the concordances are still pretty high.
I ti sn o tu n e x p e c t e dt of i n dt h eh i g hc o n c o r d a n c ea m o n g
the different platforms in terms of biological functions.
Table 3: Cross-platform comparison of top 10 functions obtained from IPA analysis of differentially expressed genes identified from
gene expression profiles in rat kidneys exposed to aristolochic acid
Rank AFX_1 AFX_2 ABI AG1 GEH
1 neoplasia tumor tumor cancer tumorigenesis
2 cancer cancer cancer tumorigenesis neoplasia
3 tumor primary tumor neoplasia neoplasia cancer
4 primary tumor malignant tumor primary tumor tumor tumor
5 malignant tumor carcinoma malignant tumor primary tumor primary tumor
6 carcinoma inflammatory response carcinoma malignant tumor malignant tumor
7 colorectal cancer immune response genetic disorder carcinoma carcinoma
8 inflammatory response digestive organ tumor digestive organ tumor digestive organ tumor inflammatory response
9 morphogenesis dermatological disorder inflammatory disorder inflammatory disorder colorectal cancer
10 immunological disorder inflammatory disorder colorectal cancer immunological disorder endometriosis
Table 4: Cross-platform comparison of top 10 functions obtained from IPA analysis of control gene lists that were randomly chosen
from each platform
Rank AFX_1 AFX_2 ABI AG1 GEH
1 venous thrombosis hereditary hemorrhagic
telangiectasia
hypertension nodule psychological disorder
2 hypercalcemia ulcerative colitis movement hematological disorder schizophrenia
3 transmembrane potential liver failure Alzheimer's disease adiposity colitis
4 chemoattraction movement heart failure insulin resistance G-protein sigling, adenylate
cyclase inhibiting pathway
5 defasciculation arthritis concentration localization neurotransmission
6 dicarboxylic aminoaciduria dilation hypoplasia metabolic disorder guidance
7 cancer organization lissencephaly catabolism cardiovascular process
8 tumorigenesis progression ataxia with oculomotor apraxia unwinding assembly
9 polyubiquitition death co-activation permeability decidualization
10 xeroderma pigmentosum follicular carcinoma diameter abortion fibrosis
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(page number not for citation purposes)Although false positive genes generally exist in a DEG
list, most genes identified by microarrays are true DEGs
when a high threshold method is used for the selection.
When a biological process or function is changed, it
normally results from the common effects of many
genes. Therefore, even when dissimilar DEGs are present
in platform analyses, they may be still involved in the
same functions. Tan et al. compared the results from
three commercial platforms and found that only 4 of the
185 unique genes were universal whereas the common
top function, cell cycle, was identified by analysis of the
top 200 genes from the different platforms [3]. This
function reflects the differences in their samples, PANC-1
c e l l sg r o w ni ns e r u m - r i c ha n ds e r u m - f r e em e d i a .
In this study, the rats were treated with AA using a
similar protocol shown to result in the development of
tumors in the rat kidney [12]. Six-week-old rats were
treated with 10 mg AA/kg body weight five times a week
for 12 weeks. The animals were sacrificed one day after
the last treatment so that the gene expression could
reflect the carcinogenicity and toxicity induced by AA in
rat kidney. Although adenomas and adenocarcinomas in
the renal cortex and papillomas in the renal pelvis were
observed three months after the AA treatment in the
carcinogenic study, atypical cells with gigantic nuclei and
enlarged basophilic nucleoli in the tubular epiththelium
of the renal cortex and multifocal dedifferentiation of
the renal tubular epithelium and hyperplasia of the
transitional epithelium in the renal pelvis were found
immediately after the 3 month’s treatment with 10 mg/
kg AA. Therefore, the true biological differences between
AA-treated and control samples are known. If a micro-
a r r a ya n a l y s i so ft h e s es a m p l e si sr e l i a b l e ,i ts h o u l d
reflect the pathogenesis exerted by AA treatment. The
biological functions identified by the different sites or
platforms reflect the biological effects of AA treatment
(Table 3). The carcinogenesis-related functions appear in
the top list in every laboratory site or platforms. This
concordance suggests that data generated on different
microarray platforms are comparable in terms of
biological responses.
Conclusion
In this study, we analyzed and compared microarray data
generated by the MAQC project on AA-treated and
control rat kidney samples from a biological function
viewpoint. Our data demonstrated that there are high
concordances of biological functions in intra- and inter-
platform comparisons. Also, importantly, data from all
the platforms or sites revealed the ongoing biological
processes, carcinogenesis, in the kidneys of rats exposed
to AA, a known carcinogen. These results suggest that
highly consistent biological functions can be revealed
when data from different microarray platforms are
analyzed separately without restricting the analysis on
a common set of genes found on all the platforms.
Methods
Microarray dataset
The microarray expression raw data were generated
previously by the MAQC project to evaluate the
consistency among different microarray platforms [5].
The total RNAs for microarray analysis were isolated
from 12 kidney samples of Big Blue® Transgenic Fisher
344 rats. Six of these rats were treated with 10 mg AA/kg
body weight by gavage five times a week for 12 weeks
while the other 6 rats were treated with the vehicle (0.9%
sodium chloride). The treatment used induced DNA
adducts, mutations and tumors in the kidneys of the
AA-treated rats [12,16,17].
The microarray experiments were conducted at 5 test
sites, including 2 sites using the AFX platform (Rat
Genome 230 2.0). The other 3 sites used ABI (Rat
Genome Survey Microarray), AG1 (Whole Rat Genome
Oligo Microarray, G4131A) or GEH (Rat Whole Genome
Bioarray, 300031) platforms. The total RNAs were
isolated in our laboratory and distributed to each test
site. Totally, 60 microarrays were used for AA-treated and
control kidney samples at the 5 sites. Detailed informa-
tion about animal treatment and microarray experiments
can be found in an earlier publication [5].
Selection of differentially expressed and randomly
selected genes for functional analysis
The microarrays from the 4 platforms contain different
numbers of probes for gene expression analysis. Speci-
fically, 31099, 26857, 41071 and 35129 probes (or
probe-set for AFX) are present in AFX, ABI, AG1 and GEH
microarrays, respectively. According to Entrez gene ID,
these probes correspond to 13713, 16280, 16135 and
12576 genes in AFX, ABI, AG1 and GEH microarrays,
respectively. There are 5824 genes that are common
across all 4 platforms. In contrast to the MAQC study
that used the common genes for cross-platform compar-
ison, we used the whole gene set of each platform to
select DEGs. The data analysis was conducted using
ArrayTrack software (http://www.fda.gov/nctr/science/
centers/toxicoinformatics/ArrayTrack/index.htm). The
gene expression data were normalized by using quantile
method. Significance Analysis of Microarrays (SAM) was
used to calculate q values. Two class unpaired analysis
with 500 permutations was performed. DEGs were
selected based on q < 0.01.
Mock gene lists were created by randomly selecting genes
for each platform or site to serve as negative controls for
cross-platform comparison. To generate the control gene
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number as ID. The probes were randomly chosen by ID.
The number of genes randomly chosen from a platform/
site is the same as the number in the DEG list.
Functional analysis
Functional analysis was performed using IPA online
software. The genes in the DEG lists and the control gene
lists were uploaded into IPA. The biological meanings for
each gene list were interpreted using Core analysis,
selecting rat for the species and the Relaxed (only
molecules are filtered) for the filter. Both up- and down-
regulated genes were analyzed. Databases corresponding
to each individual platforms for AFX, ABI and AG1 and
Ingenuity Knowledge Base (Gene only) for GEH were
used for the analysis. A total of 1303, 928, 559, 611, and
2346 genes were uploaded and 1297, 924, 558, 610 and
2325 genes were eligible for function/pathway analysis
for AFX_1, AFX_2, ABI, AG1 and GEH platforms/sites,
respectively. In IPA, the functional relevance of a gene list
was evaluated at 3 levels, category, function and function
annotation. Each category includes multiple functions and
each function usually includes multiple function annota-
tions. A p value was calculated for each category/function/
function annotation by IPA to show the enrichment of the
input gene list in this category/function/function annota-
tion. The p values are calculated using the right-tailed Fisher
Exact Test by considering the number of analyzing genes
that participating in that function and the total number
of molecules that are known to be associated with that
function in Ingenuity Knowledge Base [19]. Smaller
p values indicate a higher level of enrichment in the
input gene list of genes involved in the corresponding
category/function/function annotation. The categories/
functions/function annotations with p v a l u e<0 . 0 5w e r e
considered as significantly relevant with the analyzing
genes and the top function annotations up to 500 were
generated by the IPA. The functions related to these
function annotations were selected for our analysis.
The proportion of common functions identified by
microarray analysis from the different platforms/sites
With IPA analysis, we generated 5 significant and 5
control category/function/function annotation lists. We
focused on the function level for our analysis since
similar results were found for analysis with function
annotations. Because category is a sketchy level that has
only a few of them for analysis, functions in this level
have been eliminated from our analysis. Each function
list was sorted according to p values. The repetitive
functions in a function list were merged and their
p values were averaged. The percentage of common func-
tions between two or across all of the platforms/sites
was calculated within a set of functions at a specific
rank. For example, to calculate a percentage of common
functions between platforms A and B at rank 50, the top
50 functions in both platforms were used for compar-
ison and the number of the common functions divided
by 50 would give the results. The same method was used
to calculate the percentage of common functions across
all of the platforms.
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